HECHI CHEMICAL(SZ:000953)2025-01-20 10:55Financial Performance Expectations - The company expects a net profit attributable to shareholders of between 78 million and 86 million yuan for 2024, compared to a loss of approximately 11.56 million yuan in the same period last year[3]. - The projected net profit after deducting non-recurring gains and losses is estimated to be between 3.6 million and 5.4 million yuan, recovering from a loss of about 12.03 million yuan in the previous year[3]. - The expected basic earnings per share are between 0.2130 yuan and 0.2349 yuan, a significant improvement from a loss of 0.0316 yuan per share in the prior year[3]. - The anticipated operating revenue is projected to be between 190 million and 250 million yuan, slightly up from 187.5 million yuan in the same period last year[3]. Non-Recurring Gains - The company transferred a urea production capacity of 350,000 tons/year, generating a non-recurring gain of approximately 76 million yuan[5]. Subsidiary Performance - The subsidiary, Nansong Pharmaceutical, has successfully expanded its market presence, leading to an increase in both operating revenue and net profit[5]. Financial Reporting and Auditing - The financial data provided is preliminary and has not been audited, with the final figures to be confirmed in the 2024 annual report[4]. - The company will closely monitor the audit progress and will revise the earnings forecast if there are significant discrepancies with the actual results[7]. - The company emphasizes the importance of cautious decision-making for investors due to the preliminary nature of the earnings forecast[7]. Information Disclosure - The designated media for information disclosure includes "China Securities Journal," "Securities Times," and the Giant Tide Information Network[8].